Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation
CD34+ Stem Cell Infusion in Post Intestinal Transplant Patients
Sponsor: Ossium Health, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS8908
U.S. Govt. ID: NCT04804891
Contact: Transplant Clinical Research Center: /
Additional Study Information: The purpose of this study is to study the safety and feasibility of giving intestinal transplant patients CD34+ stem cells (the cells that make all the types of blood cells) obtained from their organ donor's bonemarrow as an IV infusion post-transplant. Researchers will be looking to see whether this CD34+ cell infusion might help control rejection of the new organ while reducing the risk of infection and disease associated with transplant medications. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Tomoaki Kato, MD
Do You Qualify?
Are you between 18 and 65 years old? Yes No
Are you on the waiting list for an intestinal or multi-visceral transplant? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Transplant Clinical Research Center